Loading…
Each decision rolls up every audited claim behind one longevity question — what each creator said, how it stacks up against the literature, and the verdict.
Ignore IV NAD+. NMN/NR oral supplements: Watch.
For statin-myalgia and for heart-failure: targeted yes. For general longevity: limited evidence.
For deficient subjects: yes. For replete subjects: VITAL was mostly null — don't expect more than baseline correction.
For low-intake subjects: defensible. The internet enthusiasm runs ahead of the specific-form evidence.
COSMOS-Mind hints at cognitive benefit; cardiovascular trials are largely null. Weaker case than it looks.